Fosun International Limited has reported its financial results for the first half of 2025, highlighting a total revenue of RMB87.28 billion. The Group noted an industrial operation profit of RMB3.15 billion and a profit attributable to owners of the parent amounting to RMB661.2 million. The Group's four core subsidiaries - Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group - collectively contributed RMB63.61 billion, representing 73% of the total revenue. The company has achieved a significant milestone in its globalization efforts, with overseas revenue now representing 53% of the total revenue. Fosun's total debt to total capital ratio was reported at 53%, maintaining a healthy debt level. Credit rating agency S&P has affirmed Fosun's credit metrics with a "Stable" outlook. Fosun aims to increase its overseas revenue share further while reducing its interest-bearing debt to around RMB60 billion or less. The Group is also focused on achieving RMB10 billion in industrial operation profit and profit attributable to owners of the parent, with plans to gradually increase its dividend payout ratio and elevate its credit rating to an investment-grade level.